作为最致命的疾病之一,胰腺癌总体预后不佳,对大多数治疗方式有很高的抵抗力。此外,胰腺癌在可治愈期无法早期发现,因为早期症状很少出现,并且尚未发现该疾病的特异性标志物。虽然新药的组合,多模式疗法,和佐剂延长生存期,大多数患者在手术后仍然复发并最终死亡。因此,寻找更有效的胰腺癌治疗方法是高度相关和合理的.作为一个新发现的天然气传输调停者,硫化氢(H2S)承担着重要的功能,包括占据人类生物学关键过程的各种信号复合物。越来越多的证据表明H2S表现出癌症发展的双峰调节。因此,内源性或低水平的外源性H2S被认为会促进癌症,而高剂量的外源性H2S抑制肿瘤增殖。同样,抑制内源性H2S产生也抑制肿瘤增殖。因此,H2S生物合成抑制剂和H2S补充(H2S供体)是两种不同的治疗癌症的策略。不幸的是,到目前为止,尚未研究内源性H2S对胰腺癌的调节。然而,H2S供体及其衍生物已被广泛研究为通过抑制细胞增殖来治疗胰腺癌的潜在治疗剂。诱导细胞凋亡,阻止细胞周期,并通过利用多种信号通路抑制入侵和迁移。据我们所知,目前尚无关于H2S供体对胰腺癌影响的综述。基于这些担忧,本文总结了部分H2S供体和NO-H2S双重供体对胰腺癌的治疗作用。外源性H2S供体可能是用于胰腺癌治疗的有希望的化合物。
As one of the most lethal diseases, pancreatic cancer shows a dismal overall prognosis and high resistance to most treatment modalities. Furthermore, pancreatic cancer escapes early detection during the curable period because early symptoms rarely emerge and specific markers for this disease have not been found. Although combinations of new drugs, multimodal therapies, and adjuvants prolong survival, most patients still relapse after surgery and eventually die. Consequently, the search for more effective treatments for pancreatic cancer is highly relevant and justified. As a newly re-discovered mediator of gasotransmission, hydrogen sulfide (H2S) undertakes essential functions, encompassing various signaling complexes that occupy key processes in human biology. Accumulating evidence indicates that H2S exhibits bimodal modulation of cancer development. Thus, endogenous or low levels of exogenous H2S are thought to promote cancer, whereas high doses of exogenous H2S suppress tumor proliferation. Similarly, inhibition of endogenous H2S production also suppresses tumor proliferation. Accordingly, H2S biosynthesis inhibitors and H2S supplementation (H2S donors) are two distinct strategies for the treatment of cancer. Unfortunately, modulation of endogenous H2S on pancreatic cancer has not been studied so far. However, H2S donors and their derivatives have been extensively studied as potential therapeutic agents for pancreatic cancer therapy by inhibiting cell proliferation, inducing apoptosis, arresting cell cycle, and suppressing invasion and migration through exploiting multiple signaling pathways. As far as we know, there is no review of the effects of H2S donors on pancreatic cancer. Based on these concerns, the therapeutic effects of some H2S donors and NO-H2S dual donors on pancreatic cancer were summarized in this paper. Exogenous H2S donors may be promising compounds for pancreatic cancer treatment.